B-cell activating factor (BAFF) is a key regulator of B-lymphocyte development. Its biological role is mediated by the specific receptors BCMA, TACI and BAFF-R. We have determined the crystal ...
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE), IgA nephropathy, and ...
Luminary Therapeutics Announces FDA Clearance of IND for LMY-920, a Novel BAFF CAR T-Cell Therapy to Treat Systemic Lupus Erythematosus (SLE). MINNEAPOLIS, MN, UNITED ...
University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial. He says in the two years since the foundational pre-clinical work was completed, the ...
Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback